Teacher Retirement System of Texas Acquires 1,856 Shares of Soleno Therapeutics, Inc. $SLNO

Teacher Retirement System of Texas raised its stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 26.7% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 8,796 shares of the company’s stock after purchasing an additional 1,856 shares during the period. Teacher Retirement System of Texas’ holdings in Soleno Therapeutics were worth $737,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SLNO. Envestnet Asset Management Inc. lifted its holdings in shares of Soleno Therapeutics by 32.9% in the second quarter. Envestnet Asset Management Inc. now owns 5,866 shares of the company’s stock valued at $491,000 after purchasing an additional 1,453 shares in the last quarter. Nisa Investment Advisors LLC raised its position in Soleno Therapeutics by 287.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 539 shares of the company’s stock valued at $45,000 after buying an additional 400 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Soleno Therapeutics in the 2nd quarter valued at $1,081,000. Mutual of America Capital Management LLC lifted its stake in Soleno Therapeutics by 7.8% during the 2nd quarter. Mutual of America Capital Management LLC now owns 78,254 shares of the company’s stock valued at $6,556,000 after acquiring an additional 5,672 shares in the last quarter. Finally, TD Asset Management Inc boosted its holdings in Soleno Therapeutics by 34.9% during the 2nd quarter. TD Asset Management Inc now owns 99,810 shares of the company’s stock worth $8,362,000 after acquiring an additional 25,800 shares during the last quarter. 97.42% of the stock is owned by institutional investors.

Soleno Therapeutics Stock Up 9.6%

Soleno Therapeutics stock opened at $47.70 on Friday. The firm has a 50 day moving average price of $62.30 and a 200-day moving average price of $72.92. The company has a quick ratio of 15.01, a current ratio of 15.13 and a debt-to-equity ratio of 0.21. Soleno Therapeutics, Inc. has a twelve month low of $41.50 and a twelve month high of $90.32. The company has a market capitalization of $2.54 billion, a P/E ratio of -11.52 and a beta of -2.92.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.39. The company had revenue of $66.02 million during the quarter, compared to the consensus estimate of $47.46 million. As a group, equities analysts predict that Soleno Therapeutics, Inc. will post -3.72 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on SLNO. Oppenheimer increased their target price on shares of Soleno Therapeutics from $105.00 to $110.00 and gave the company an “outperform” rating in a report on Thursday, August 7th. Robert W. Baird set a $121.00 price objective on shares of Soleno Therapeutics and gave the company an “outperform” rating in a research note on Friday, July 11th. Wall Street Zen raised shares of Soleno Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday. Guggenheim reaffirmed a “buy” rating and issued a $106.00 target price on shares of Soleno Therapeutics in a report on Wednesday, August 27th. Finally, The Goldman Sachs Group set a $125.00 price target on Soleno Therapeutics and gave the company a “buy” rating in a research report on Tuesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $114.50.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.